The discovery of radium by Pierre and Marie Curie in December 1898 opened a new era in science and within a few years provided medicine with a new means of tumor treatment. Their personal contribution to the start and early development of clinical applications should not be overlooked. The Curies did not limit their support to providing radium sources to medical pioneers but took a deep interest in the horizons of radium therapy. Pierre was one of the first to search for and demonstrate a biological effect of radium radiation. He investigated the radioactivity of the waters of hydrotherapeutic resorts. Marie took care of the measurement of the medical sources personally, convinced that the result of the treatment depends on the precise knowledge of the amount of radium applied. Her perseverance resulted in the establishment of the Institut du Radium (1909) in which, besides the physico-chemical laboratory, a biological department was set up. The latter became the Fondation Curie (1920), a leading medical center of treatment and training, with an integrated team of physicists, radiobiologists and clinicians led by Regaud. One hundred years after the discovery of radium, patients benefit today from the extensive clinical experience that has been collected over the years and from sophisticated developments in application techniques, dosimetry and quality assurance; the professional risk has been precisely assessed and the improvements in material and procedure have enabled the medical personnel to work in hazard-free conditions. This outcome results from the continuous progress that the pioneers gave impulse to. This paper intends to recall their efforts and achievements, as well as the difficulties and the problems they encountered during the first 2 decades when the sturdy foundations of brachytherapy were built.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0167-8140(98)00137-6 | DOI Listing |
Cureus
August 2024
Internal Medicine, Wellstar Health System, Marietta, USA.
Cureus
August 2024
Oncology/Radiation Oncology, Tawam Hospital, Al Ain, ARE.
Marie Curie, a distinguished physicist and chemist, profoundly transformed the fields of radiology and medicine through her pioneering research on radioactivity. As the first woman to win a Nobel Prize and the only person to win in two different scientific fields, Physics (1903) and Chemistry (1911), Curie's achievements have left an indelible mark on medical science. This historical vignette explores her groundbreaking discoveries, including the isolation of radium and polonium, and her innovative applications of radioactivity in medicine, particularly in the treatment of cancer.
View Article and Find Full Text PDFAnn Rev Mar Sci
August 2024
School of the Earth, Ocean, and Environment, College of Arts and Sciences, University of South Carolina, Columbia, South Carolina, USA; email:
My strategy for writing this autobiography is to use examples of how working on seemingly different projects can often lead to outcomes more important than originally envisioned. Serendipity is a happy accident-specifically, the accident of discovering something useful without directly looking for it. This often occurs when two research projects converge unexpectedly.
View Article and Find Full Text PDFClin Epigenetics
April 2024
Women's Malignancies Program, Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Rm 144, CRB1, Baltimore, MD, 21231, USA.
Background: Cervical cancer remains a leading cause of death, particularly in developing countries. WHO screening guidelines recommend human papilloma virus (HPV) detection as a means to identify women at risk of developing cervical cancer. While HPV testing identifies those at risk, it does not specifically distinguish individuals with neoplasia.
View Article and Find Full Text PDFSmall
March 2024
Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Radium-223 ( Ra) is the first-in-class alpha-emitter to mediate tumor eradication, which is commonly thought to kill tumor cells by directly cleaving double-strand DNA. However, the immunogenic characteristics and cell death modalities triggered by Ra remain unclear. Here, it is reported that the Ra irradiation induces the pro-inflammatory damage-associated molecular patterns including calreticulin, HMGB1, and HSP70, hallmarks of tumor immunogenicity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!